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Abstract 
HDAC1 is a Class I histone deacetylase (HDACs) 
encoded by this gene. HDACs remove acetyl group 
from amino-terminal tail of histone lysine recovering 
the positive charge of histone tail, permitting 
interactions between negatively charged DNA and 
histone protein, resulting in chromatin structure 
condensation which is associated with gene 
repression. Overexpression of this protein has been 
related to several malignancies, controlling tumour 
suppressor genes expression, feasible prognostics 
factor, and medications target. This paper propound 
data about HDAC1 gene, its protein encoded and 
function. 
Keywords 
Histone deacetylase 1, gene expression regulation, 
epigenetic repression. 
Identity 
Other names 
RPD3, RPD3L1, GON-10, HD1 
HGNC (Hugo) 
HDAC1 
Location 
1p35.2-p35.1 
DNA/RNA 
Description 
Located in chromosome 1. The entire HDAC1 gene 
is approximately 41,550 bases (start: 32,292,086 
and end: 32,333,635 bp; orientation: Plus strand) and 
contains 14 exons. 
Protein 
Description 
HDAC1 protein consists of 482 amino acids with a 
molecular theoretical weight of 55.18 kDa. 
Human HDAC1 protein (GenBank Accession No. 
NM_004964), full length with C-terminal His-tag 
and C-terminal FLAG-tag, MW = 56 kDa, expressed 
in baculovirus expression system. Recombinant 
HDAC1 forms a complex with endogenous HSP70 
and is co-purified with tubulin. The identity of 
Hsp70 and tubulin was confirmed by MALDITOF 
mass spectrometry. 
Expression 
Ubiquitously. 
Localisation 
HDAC1 is found mainly in the nucleus. 
Function 
HDAC1 is an enzyme responsible for epigenetic 
alterations leading to modulation of chromatin 
structure and transcriptional regulation across lysine 
residues deacetylation on the N-terminal part of the 
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core histones (H2A, H2B, H3 and H4) (Fig. 1). It 
shows a role in cell cycle regulation and 
haematopoiesis (Dovey, et al. 2010). Deacetylation 
of TP53 by HDAC1 is a mechanism that participate 
of physiological activity of TP53 (Juan, et al. 2000 
2000). It was also observed an important 
participation in cellular proliferation through direct 
regulation of CDKN1A (p21) gene (Zupkovitz, et al. 
2010) 2010. HDAC2 is a HDAC1 homologue that, 
in part, compensates its loss and has redundant 
functions (Zupkovitz, et al. 2006 2006). These 
enzymes act through multiprotein co-repressor 
complexes such as: SIN3, NuRD, RCOR1 
(CoREST) (Kelly and Cowley 2013). 
 
Fig. 1. Chromatin remodeling by histone acetylation 
changes. HATs catalyse the addition of acetyl groups 
turning histone tail charge to negative, leading to 
chromatin opening, while HDACs remove acetyl 
group from amino-terminal tail of histone lysine 
recovering its positive charge, closing the chromatin 
structure. 
Homology 
HDAC1 shares high homology between diverse 
species (Table 1). 
 
Table 1. Comparative identity of human HDAC1 
and its homologs in other species). 
 
Gene  Identity 
H. sapiens vs. Symbol Protein DNA 
P. troglogytes HDAC1 99.8 99.4 
P. troglogytes HDAC1 99.6 99.4 
M. mulata  LOC708441 99.8 97.8 
C. lupus HDAC1 99.2 94.1 
B. taurus HDAC1 99.2 93.9 
M. musculus Hdac1 99.4 90.5 
R. norvegicus Hdac1 99.2 90.9 
G. gallus Hdac1 93.3 79.2 
D. melanogaster  Rpd3 82.1 72.2 
A. gambiae AgaP_AGAP006511 83.1 72.8 
C. elegans hda-3 69.5 63.5 
S. cerevisiae RPD3 64.8 60.3 
K. lactis KLLA0E01981g 65.4 61.2 
E. gossypii AGOS_AGR395W 65.0 62.2 
S. pombe clr6 64.5 63.2 
M. oryzae MGG_05857 66.7 63.9 
N. crassa NCU00824 66.1 62.8 
A. thaliana HD1 67.6 63.4 
O. sativa Os02g02124900 68.3 64.0 
O. sativa Os06g0583400 69.2 65.4 
 
Mutations 
Note 
A total of 60 substitution missense, 5 substitution 
nonsense, 29 substitution synonymous, no insertion 
frameshift, no deletions inframe, 2 deletion 
frameshift, none complex and none other mutations 
are reported in COSMIC (Catalogue of somatic 
mutations in cancer); it was found 110 mutated 
samples from a total of 29924 tested samples. 
Implicated in 
Oral squamous cell carcinoma 
HDAC1 overexpression was found in 55.10% of 49 
mobile tongue squamous cell carcinoma evaluated 
whereas most of the cells from non-neoplastic 
epithelium presents negative immunoexpression for 
HDAC1 (Theocharis, et al. 2011). HDAC1 was 
overexpressed in 70% of lip squamous cell 
carcinoma (Fig.2) and in 77% of actinic cheilitis, 
with immunoexpression increasing in preneoplastic 
cases with severe epithelial dysplasia, and in 
neoplastic cases with poor differentiation (Chrun, et 
al. 2017). 
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Fig. 2. Immunoexpression of HDAC1 in lip squamous cell carcinoma. 
Esophageal cancer 
Comparing H4 acetylation and HDAC1 expression, 
it was observed hyperacetylation of H4 and 
decreased HDAC1 expression from esophageal 
normal tissue through esophageal carcinoma, 
suggesting that the equilibrium between HDAC and 
HAT is interrupted in this carcinoma (Toh, et al. 
2003). Few cases of esophageal cancer were reported 
with HDAC1 overexpression when compared to 
normal esophageal mucosa (15%) (Nakagawa, et al. 
2007). Esophageal adenocarcinoma also presented 
subexpression in majority of cases and was not 
associated to prognostic factor (Langer, et al. 2010). 
Thyroid cancer 
HDAC1 immunoexpression was found in 99% of 47 
thyroid malignances (papillary, follicular, 
medullary, and anaplastic thyroid carcinomas) and 
23  benign thyroid tumors, with significant relation 
to tumor size, without difference in expression 
between malignant and benign thyroid tumors 
(Giaginis, et al. 2014). Nakagawa and collaborators 
reported immunoreactivity in all evaluated cases of 
papillary thyroid tumors (Nakagawa, et al. 2007). 
Gastric cancer 
HDAC1 overexpression was detected by semi-
quantitative RT-PCR, immunoblot analysis, and 
immunohistochemistry in gastric cancer tissues 
compared to its corresponding normal tissue (Choi, 
et al. 2001; Nakagawa, et al. 2007). Sudo and 
colleagues found association between HDAC 
expression and aggressive behavior of primary 
gastric cancer. In this study, HDAC1 overexpression 
was found by quantitative reverse transcription-PCR 
in gastric cancer tissue in 77% of the cases, with 
higher expression correlated to lymph vessel and 
vascular vessel permeations, advanced stage of the 
disease, and lymph node metastasis (Sudo, et al. 
2011). 
Colorectal cancer 
When comparing colorectal carcinoma cells and 
normal colonic mucosa by reverse transcription 
(RT)-PCR (Ishihama, et al. 2007) and  
immunohistochemistry (Nakagawa, et al. 2007) 
there was a greater HDAC1 expression in cancer 
than in normal colonic epithelium.  Bernard and 
collaborators evaluated tissue microarray (TMA) 
with 254 colorectal adenocarcinomas samples and 
50 normal colorectal tissues, showing no significant 
difference between normal and cancerous tissues, 
but suggested combination of higher HDAC 
expression and clinical outcomes for these patients 
(Benard, et al. 2015). 
Pancreatic cancer 
HDAC1 with HDAC2 and SIN3A were recognized 
as complex silencing regulators of CDH1  (E-
cadherin), thus involved in pancreatic 
adenocarcinoma metastasis (von Burstin, et al. 2009; 
Aghdassi, et al. 2012). Several HDACs were 
evaluated in  (pNET): higher expression of HDAC1 
was observed in high grade pNET and its expression 
showed positive correlation with mitotic (pHH3) and 
proliferation (Ki-67) index (Klieser, et al. 2017). 
Lymphomas 
Hodgkin`s lymphoma  exhibited higher 
immunoexpression of HDAC1 when analysing 283 
TMA (Adams, et al. 2010). In diffuse large B-cell 
lymphomas (DLBCL) HDAC1 immunoexpression 
was higher in comparison to reactive lymphoid 
hyperplasia which was correlated to cell 
proliferation index (Ki67) in the development of 
DLBCL, and associated with aggressiveness/poor 
survival of DLBCL patients (Min, et al. 2012). On 
the other hand, Lee and colleagues found faintly 
nuclear staining in few cases of 91 DLBCL samples 
submitted to immunohistochemistry (Lee, et al. 
2014). 
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Leukemias 
Moreno and collaborators evaluated 94 cases of 
childhood acute lymphoblastic leukaemia (ALL) and 
found HDAC1 mRNA increased expression in T-cell 
ALL  when compared to B-cell ALL. Yang et al. also 
found higher HDAC1 mRNA in ALL. (Moreno, et 
al. 2010). Quantitative real-time polymerase chain 
reaction also revealed higher HDAC1 expression in 
ALL (Yang, et al. 2015). Clinicopathological 
parameters indicated that overexpression of HDAC1 
may be related to unfavourable prognosis of 
childhood ALL (Gruhn, et al. 2013). 
Lung cancer 
HDAC1 is highly expressed in lung cancer 
(Nakagawa, et al. 2007).  A correlation between 
HDAC1 mRNA and protein levels showed that 
HDAC1 gene expression might be involved with 
lung cancer progression (Sasaki, et al. 2004). 
Prostate cancer 
Up-regulation of HDAC1 in prostate cancer 
compared to benign prostatic hyperplasia was 
demonstrated by immunohistochemistry (Patra, et al. 
2001; Nakagawa, et al. 2007). Weichert and 
collaborators achieved immunohistochemistry for 
Class I HDAC isoforms in prostate carcinomas, 
showing HDAC1, HDAC2 and HDAC3 stronger 
expression accompanied by tumor cell proliferation 
raising (Weichert, et al. 2008). Overexpression of 
HDAC1 was also related to major increase of 
hormone refractory in prostate cancer and 
augmentation of proliferation (Halkidou, et al. 
2004). 
Breast cancer 
HDAC1 was evaluated in TMA from 238 patients 
with primary breast cancer and presented wide 
variation in positive imunnoexpression (Muller, et 
al. 2013). While Nakagawa (Nakagawa, et al. 2007) 
and Ververis (Ververis and Karagiannis 2012) 
showed higher expression of HDAC1 by 
immunohistochemistry and immunofluorescence 
respectively. Suzuki and colleagues detected a 
decrease in its expression from normal tissue 
through invasive ductal carcinoma, and from high 
grade through intermediate/low grade carcinoma 
(Suzuki, et al. 2009). Higher expression of HDAC1 
was related to molecular subtypes (Luminal A, 
Luminal B, HER overexpressed, and triple-negative) 
and with improved overall survival (Seo, et al. 
2014). 
Ovarian cancer 
HDAC1 immunoexpression showed positive 
correlation with Ki-67 and inverse correlation with 
E-cadherin in 115 cases of ovarian tumors, 
suggesting an important participation of HDAC1 in 
cellular proliferation. Its overexpression was also 
associated with poor outcome (Hayashi, et al. 2010). 
Immunoreactivity for HDAC1 was sighted in 95% of 
cases evaluated, but without significant difference 
between histological subtypes of ovarian cancer 
(Nakagawa, et al. 2007). By immunohistochemistry 
and qRT-PCR, HDAC1 and DNMT3B revealed 
positive correlation in ovarian cancer; HDAC1 was 
highly expressed in comparison to normal ovarian 
tissue (Gu, et al. 2013). In a population-based cohort 
of 465 ovarian carcinomas, Weichert and 
collaborators observed higher level expression of 
HDAC1 and positive correlation with Ki67, 
indicating its participation in cell proliferation 
without significant interference in prognostic 
(Weichert 2009). 
Endometrial cancer 
Strong HDAC1 immunoexpression was observed in 
endometrial stromal sarcoma, and it was suggested 
that this expression is linked to lower than 10 years 
disease free survival (Baek, et al. 2016). Endometrial 
adenocarcinomas compared to normal endometrium 
exhibited reduction in HDAC1 expression (Krusche, 
et al. 2005).  However, in other research, endometrial 
carcinomas presented higher HDAC1 expression in 
comparison to normal endometrial tissue (Fakhry, et 
al. 2010). Weichert and colleagues evaluated 149 
endometrial carcinomas and showed a higher level 
of HDAC1 expression that was positively correlated 
with cell proliferation indicator (Ki-67) and 
associated to 10 years  survival decrease (Weichert 
2009). 
To be noted 
High expression of HDAC1 was found in majority 
of cancer types studied. Epigenetic alterations are 
heritable and reversible phenomenon; thus, these 
histone modifiers proteins represent targets to 
antineoplastic agents, with some medications 
(belinostat, vorinostat, and romidepsin) already 
approved by Food and Drugs Administration for 
treatment of hematological malignances. HDAC 
inhibitors have been studied with potential outcomes 
to improve conventional therapy in several tumors. 
These findings may expand cancer treatment 
strategies in a short time. 
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